Skye Bioscience, Inc. Material Event: Nasdaq Listing Update

This guide explains the latest news from Skye Bioscience in plain English. If you follow their stock or are just curious, here is what you need to know.

1. What happened?

Nasdaq notified Skye Bioscience that it no longer meets the requirements to stay listed on the Nasdaq Global Market. The company’s "stockholders’ equity"—the net value of the company—dropped to about $9 million. Nasdaq requires at least $10 million to remain listed.

2. Why did it happen?

Skye Bioscience is a drug-development company that does not yet sell products or earn revenue. It spends heavily on research, clinical trials, and daily operations. Because the company is in this expensive development phase, its net value dropped below the $10 million threshold.

3. Why does this matter?

While this is a regulatory issue, it is a common hurdle for young biotech firms.

• The Good News: This notice has no immediate effect on your ability to trade the stock. It continues to trade under the ticker "SKYE" as usual.
• The Reality Check: The company must now prove it can regain and maintain the required level of net value to satisfy Nasdaq’s rules.

4. Who is affected?

• Investors: You may see more stock price volatility as the market reacts to this news.
• The Company: Management must now find ways to boost the company’s net value. They might raise more money by selling more shares (which can dilute your ownership percentage), restructure debt, or take other financial actions.
• Patients: This is an administrative issue. It does not change the company’s scientific goals or its ongoing clinical trials.

5. What happens next?

Skye must submit a plan to Nasdaq by June 29, 2026, explaining how it will fix the issue. If Nasdaq accepts the plan, they may give the company until November 9, 2026, to meet the requirements. If the company fails to comply by the deadline, it risks being removed from the Nasdaq exchange.

6. What should investors consider?

• Don’t panic: This is a rule-compliance issue, not a bankruptcy filing.
• Watch for the plan: Keep an eye on future company filings. The way they choose to increase their net value will show you their long-term strategy and whether they plan to issue more shares, which could impact the value of your current holdings.
• Understand the risk: Biotech stocks are high-risk. These companies depend on successful drug testing and their ability to keep enough cash on hand to satisfy exchange rules.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and does not constitute financial advice. Always do your own research before making investment decisions.